Quarterly Results
BBIO Earnings Forecast
Looking ahead, BBIO remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 148.12M and an EPS of -0.66.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 4.68%, while EPS estimates have been Revise Upward by 5.76%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Upward by 15.23% . These revisions correlate with a 38.05% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in BBIO long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
1Y
3Y
5Y
Currency: USD
--
Revenue Estimate-:0
--
EPS Estimate-:0
—
Stock Price0
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Al Analysis
Earnings Surprise Analysis
Revenue
EPS
1Y
3Y
Al Analysis
Earnings Reaction
The chart below shows how BBIO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BBIO sees a -2.45% change in stock price 10 days leading up to the earnings, and a -2.65% change 10 days following the report. On the earnings day itself, the stock moves by +0.62%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed -4.88% on the day following the earnings release and then changed by -0.60% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
People Also Watch
Frequently Asked Questions
What were the key highlights of BBIO's latest earnings report for FY2025Q3?
BBIO reported its FY2025Q3 earnings on 2025-10-29, showcasing a revenue of 120.70M against an estimate of 106.05M, resulting in a 13.81% surprise. The EPS was -0.95, surpassing the expected -0.88 by -7.95% . The stock experienced a -4.88% price change on the earnings day and a -7.88% change over the next five days, reflecting market reactions to the results.
How did BBIO's stock price react after the FY2025Q3 earnings release?
Following BBIO's FY2025Q3 earnings announcement on 2025-10-29, the stock price moved by -4.88% on the day of the release. Over the subsequent five days, it saw a -7.88% change. Historically, BBIO's stock price tends to shift by an average of -2.45% in the 10 days leading up to earnings and -2.65% in the 10 days following, providing insight into potential market.
What are the revenue and EPS estimates for BBIO for 2025/Q4?
For 2025/Q4, analysts estimate BBIO’s annual revenue to reach 148.12M, while the EPS is projected at -0.66. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 4.68% and EPS estimates Revise Upward by 15.23% over the past three months, indicating analyst expectation in the company’s performance.
How does BBIO's stock price correlate with earnings forecast revisions?
The correlation between BBIO's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 4.68%, while EPS estimates moved Revise Upward by 15.23% . This trend suggests that price dips could present buying opportunities for investors.
What should investors expect from BBIO's next earnings report?
Based on historical trends, BBIO's stock price typically moves by -2.45% in the 10 days before its earnings and -2.65% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.66 and revenue of 148.12M.
What is the sentiment in BridgeBio Pharma Inc (BBIO) Q3 2025 Earnings Call Summary?
The earnings call highlights strong revenue growth, promising product development, and a robust cash position. Despite increased expenses, the company maintains significant cash reserves. The Q&A reveals positive sentiment towards market dynamics and strategic positioning, with growth in patient share and prescriber engagement. Management's confidence in product efficacy and market potential further supports a positive outlook. The market cap indicates a moderate reaction, suggesting a stock price increase in the range of 2% to 8% over the next two weeks.
